Suggested remit: To appraise the clinical and cost effectiveness of pegcetacoplan within its marketing authorisation for treating adults with geographic atrophy.
As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Pegcetacoplan for treating geographic atrophy [ID4041] For information, the company have advised that they did not receive Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Further information:
- Scoping commencing
- Process:
- STA Standard
- ID number:
- 4041
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Peninsula Technology Assessment Group (PenTAG), University of Exeter
Stakeholders
- Companies sponsors
- Apellis (pegcetacoplan)
- Others
- Department of Health and Social Care
- NHS England
- Welsh Government
- Patient carer groups
- Macular Society
- Professional groups
- Royal College of Ophthalmologists
- Royal College of Physicians
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 13 February 2025 | Suspended. As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Pegcetacoplan for treating geographic atrophy [ID4041] For information, the company have advised that they did not receive Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 03 April 2024 | Following a regulatory update from the company, the timelines for this appraisal are to be confirmed. |
| 16 August 2023 | Invitation to participate |
| 19 July 2023 | Stakeholder workshop |
| 26 May 2023 - 26 June 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4041 |
| 26 May 2023 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual